Skip to main content
. 2021 Oct 8;13(19):5026. doi: 10.3390/cancers13195026

Figure 3.

Figure 3

Adoptive cellular therapies for MDS and AML. Newer cellular therapies include chimeric antigen receptor T-cell (CAR T-cells) directed against natural killer group 2D (NKG2D), CD123, FLT3, and C-type lectin-line molecule-1 (CLL1), and CD70 expressed on MDS and AML cells. Another recent approach is to employ adoptive transfer of haploidentical natural killer (NK) cells to target and eradicate MDS and AML cells. Image created with BioRender.com.